Mustafa Çobaner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mustafa Çobaner has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ali Evren Tufan
Department of Child and Adolescent Psychiatry, Bolu Abant İzzet Baysal University Medical Faculty, Bolu, Turkey
3 shared publications - Ayşegül Danış
Department of Pediatric Neurology, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu, Turkey
1 shared publication - Canan Ayvat
Department of Psychiatry, Bolu Abant Izzet Baysal University Medical Faculty
1 shared publication - Güler Göl Özcan
Department of Child and Adolescent Psychiatry, Bilecik Seyh Edebali University Faculty of Medicine, Bilecik
1 shared publication Mesut Sari
1 shared publication- Mesut Sari
Department of Child and Adolescent Psychiatry, Bolu Abant İzzet Baysal University Faculty of Medicine
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Oculogyric Crisis and Torticollis Temporally Associated With Short-Term Coadministration of Fluoxetine and Hydroxyzine in a Child With Attention-Deficit/Hyperactivity Disorder
Was not provided for this article.
- 20 July 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Open AccessOculogyric Crisis and Torticollis Temporally Associated With Short-Term Coadministration of Fluoxetine and Hydroxyzine in a Child With Attention-Deficit/Hyperactivity Disorder
Was not provided for this article.
- 19 June 2026
- Published by Taylor & Francis in Substance Use & Misuse
- p. 1-10
Non-Medical Methylphenidate Use Among Medical Students: Prevalence and Association with Type A Personality Traits
To estimate the prevalence of non-medical methylphenidate use (NMU) in Turkish medical students and its association with Type A personality. This cross-sectional study surveyed 600 of 1,275 invited medical students (47.1%) at a single public medical faculty in Türkiye in 2025. A sociodemographic/methylphenidate-use questionnaire and the Type A Personality Traits Scale were administered. NMU was operationalized as methylphenidate use for academic or social performance enhancement in students without clinician-diagnosed ADHD, regardless of prescription status. Type A differences were tested with MANOVA. Given the low event count, Firth penalized logistic regression served as the primary multivariable analysis, with standard logistic regression reported for comparison. Lifetime methylphenidate use was 6.8% (n = 41) and current use 2.2% (n = 13); 23 students (3.8%) met NMU criteria, most commonly for academic enhancement. Awareness of methylphenidate and of peer use rose markedly from preclinical to clinical years, whereas actual use did not. Type A scores did not differ between NMU and non-NMU students. In the Firth model, peer NMU awareness and past psychiatric consultation remained associated with NMU; tentative inverse associations for male sex and the standardized Type A score should be interpreted as exploratory given the low events-per-variable ratio (3.3). NMU prevalence was low and more closely linked to contextual correlates-peer exposure and prior psychiatric contact-than to Type A traits, which did not show a robust or stable association across analyses. Multivariable findings require replication. Prevention may benefit from focusing on peer-network dynamics and mental-health support rather than personality-based risk profiling.
- 19 June 2026
- Published by Taylor & Francis in Substance Use & Misuse
- p. 1-10
Non-Medical Methylphenidate Use Among Medical Students: Prevalence and Association with Type A Personality Traits
To estimate the prevalence of non-medical methylphenidate use (NMU) in Turkish medical students and its association with Type A personality. This cross-sectional study surveyed 600 of 1,275 invited medical students (47.1%) at a single public medical faculty in Türkiye in 2025. A sociodemographic/methylphenidate-use questionnaire and the Type A Personality Traits Scale were administered. NMU was operationalized as methylphenidate use for academic or social performance enhancement in students without clinician-diagnosed ADHD, regardless of prescription status. Type A differences were tested with MANOVA. Given the low event count, Firth penalized logistic regression served as the primary multivariable analysis, with standard logistic regression reported for comparison. Lifetime methylphenidate use was 6.8% (n = 41) and current use 2.2% (n = 13); 23 students (3.8%) met NMU criteria, most commonly for academic enhancement. Awareness of methylphenidate and of peer use rose markedly from preclinical to clinical years, whereas actual use did not. Type A scores did not differ between NMU and non-NMU students. In the Firth model, peer NMU awareness and past psychiatric consultation remained associated with NMU; tentative inverse associations for male sex and the standardized Type A score should be interpreted as exploratory given the low events-per-variable ratio (3.3). NMU prevalence was low and more closely linked to contextual correlates-peer exposure and prior psychiatric contact-than to Type A traits, which did not show a robust or stable association across analyses. Multivariable findings require replication. Prevention may benefit from focusing on peer-network dynamics and mental-health support rather than personality-based risk profiling.